{"id":"W3136212749","doi":"10.1016/j.ejca.2021.01.053","title":"Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society; National Institutes of Health; Novartis Pharmaceuticals Corporation; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Hazard ratio; Breast cancer; Chemotherapy; Oncology; Gastroenterology; Confidence interval; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001848964,0.0001528385,0.0003338462,0.00005248887,0.00008373012,0.0001131452,0.0005990023,0.00003053335,0.002587],"category_scores_gemma":[0.001373792,0.000103387,0.0002030393,0.0002756363,0.0001076372,0.0001016551,0.000134977,0.0008230987,0.0001360549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002779095,"about_ca_system_score_gemma":0.001509471,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008116994,"about_ca_topic_score_gemma":0.0001011901,"domain_scores_codex":[0.996784,0.0005190456,0.0009145621,0.0002690687,0.001241332,0.0002720066],"domain_scores_gemma":[0.9975182,0.0002569896,0.0004749888,0.0004392591,0.001052491,0.0002580493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.08705505,0.0003973864,0.0003529226,0.00001071682,0.0007590345,0.005205392,0.00125848,0.00009402994,0.0153211,0.00002355838,0.725881,0.1636413],"study_design_scores_gemma":[0.1183256,0.0004681812,0.002406219,0.0005030474,0.0001023268,0.0001095395,0.0002274011,0.00007041006,0.005318761,0.00002023886,0.8723416,0.0001067093],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8279341,0.0121166,0.000392236,0.09863912,0.008512754,0.000496739,0.0005146719,0.00003824148,0.05135554],"genre_scores_gemma":[0.9470206,0.006625859,0.0008438283,0.005958047,0.01882835,0.00000550781,0.0001323905,0.00008961769,0.02049581],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1635346,"threshold_uncertainty_score":0.9983248,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1183897931597474,"score_gpt":0.4161039780804137,"score_spread":0.2977141849206663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}